Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$4.99
-AU$0.02(-0.35%)
At close: 4:00 PM EDT
AU$4.99
-AU$0.02(-0.35%)
Day’s Range― - ―
52-Week RangeAU$2.14 - AU$6.49
Previous CloseN/A
Volume465.77K
Average Volume (3M)1.50M
Market Cap
AU$624.32M
Enterprise ValueAU$920.15
Total Cash (Recent Filing)AU$74.17M
Total Debt (Recent Filing)AU$247.00K
Price to Earnings (P/E)―
Beta2.63
Next Earnings
Mar 02, 2027EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding163,433,620
10 Day Avg. Volume2,985,473
30 Day Avg. Volume1,503,330
Financial Highlights & Ratios
PEG Ratio6.46
Price to Book (P/B)11.56
Price to Sales (P/S)32321.70
P/FCF Ratio-56.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.00Price Target Upside20.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)AU$6.88M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces near-term solvency and interest burdens, preserving more financial flexibility than a highly leveraged balance sheet. This provides Artrya with greater capacity to direct available capital toward product development and commercialization while limiting debt-related constraints.
Focused AI Cardiovascular PlatformA focused platform addressing cardiovascular disease detection and clinical decision support gives Artrya a clear product identity within digital health. Embedding AI analysis into diagnostic workflows could support repeat clinical use if the software gains provider adoption.
Recurring Software Revenue ModelLicensing, subscription, and per-scan structures can create repeatable revenue tied to installed sites, users, or study volumes rather than relying solely on one-time sales. If commercial adoption develops, this model may support scalable revenue and broader deployment.
Bears Say
Minimal Revenue ScaleThe very small revenue base indicates that Artrya has not yet demonstrated meaningful commercial scale despite its healthcare software focus. This limits internally generated resources for expansion and leaves future progress highly dependent on converting the product into material customer revenue.
Widening Net LossesRapidly increasing losses show that current operating costs substantially exceed the revenue base and that profitability has not yet begun to improve. Unless revenue growth eventually outpaces spending, continued losses can consume capital and make sustainable earnings more distant.
Persistent Cash BurnPersistent negative operating and free cash flow means the business is not funding its activities internally. The further deterioration in 2026 increases dependence on external funding and may constrain investment capacity if capital becomes less available or fundraising continues.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$2.14 and its highest was AU$6.49 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$624.32M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Mar 02, 2027 which is in 158 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Aug 19, 2026. The company reported -AU$0.089 earnings per share for the quarter, missing the consensus estimate of -AU$0.055 by -AU$0.034.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate is -0.08.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 163,433,620 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.089 in its last earnings report, missing expectations of -AU$0.055. Following the earnings report the stock price went down -1.274%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.00 (20.24% Upside)
AU$6.00 (20.24% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
70.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
260.49%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Artrya Limited
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.00
▲(20.24% Upside)
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
Alcidion Group Limited
―









